PharVision Advisers’s Cinemark Holdings CNK Stock Holding History

PharVision Advisers’s Portfolio CNK Stock Details CNK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,837	Closed	-$388K	–	737
2025 Q3	$388K	Buy	13,837 +2,285	+20%	+$63.1K	0.22%	94
2025 Q2	$349K	Buy	+11,552	New	+$349K	0.5%	46
2025 Q1	–	Sell	-8,952	Closed	-$277K	–	310
2024 Q4	$277K	Buy	+8,952	New	+$277K	0.23%	184

Other funds holding CNK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lavaca Capital Houston, Texas $564M AUM 4.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PharVision Advisers's CNK Position: Q4 2025 in Review

PharVision Advisers sold out of Cinemark Holdings (CNK) in Q4 2025, closing a stake of 13,837 shares — an estimated $388K sold.

PharVision Advisers first reported a position in CNK in Q4 2024 and held it in 3 quarters. The position peaked at $388K in Q3 2025. 272 funds tracked by Wall St. Rank hold CNK as of Q4 2025.

PharVision Advisers reported no remaining Cinemark Holdings position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 13,837 Cinemark Holdings shares in Q4 2025, an estimated $388K.
PharVision Advisers first reported a position in Cinemark Holdings in Q4 2024 and held it in 3 quarters.
PharVision Advisers's Cinemark Holdings position peaked at $388K in Q3 2025.
272 funds tracked by Wall St. Rank held Cinemark Holdings as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.